广济药业(000952) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥160,264,829.93, representing a 4.73% increase year-over-year, while the year-to-date revenue reached ¥536,281,129.73, up 12.59% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was a loss of ¥4,788,962.79, a decrease of 133.11% year-over-year, and the year-to-date net profit was ¥19,907,205.68, down 73.16% compared to the previous year[5] - Total operating revenue for the third quarter reached ¥536,281,129.73, an increase of 12.6% compared to ¥476,334,358.27 in the same period last year[24] - Net profit for the quarter was ¥18,272,970.78, a decrease of 74.2% from ¥70,762,725.31 in the previous year[25] - The total comprehensive income for Q3 2022 was CNY 18,261,637.36, a decrease from CNY 70,728,188.49 in the same period last year[26] - The net profit attributable to the parent company was CNY 19,895,872.26, down from CNY 74,148,944.93 year-on-year[26] - Basic earnings per share for Q3 2022 were CNY 0.0564, compared to CNY 0.2156 in Q3 2021[26] Expenses and Costs - The company reported a significant increase in R&D expenses, which rose by 77.99% to ¥51,573,922.12, primarily due to investments in optimizing the fermentation process for Vitamin B2 and other pharmaceutical formulation projects[8] - Total operating costs amounted to ¥528,709,910.51, up 26.2% from ¥419,085,867.85 year-on-year[24] - The company’s sales expenses increased by 49.22% to ¥23,252,236.24, driven by expanded marketing channels and increased advertising costs[8] - The company reported a decrease in investment income of 73.72%, amounting to ¥4,942,171.01, due to significant fluctuations in profits from its associate company[8] Assets and Liabilities - Total assets as of September 30, 2022, were ¥2,351,308,234.63, reflecting a 14.76% increase from the end of the previous year[5] - Current assets totaled ¥919,980,790.18, a rise of 29.6% from ¥708,955,538.71 at the start of the year[21] - The company’s total liabilities increased to ¥893,136,460.65, compared to ¥598,092,478.58 in the previous year[22] - Long-term borrowings rose significantly to ¥252,855,000.00 from ¥34,450,000.00 year-on-year[22] - The equity attributable to shareholders of the parent company was ¥1,468,476,833.80, slightly up from ¥1,462,474,772.88 year-on-year[22] Cash Flow - The company experienced a 100.85% decline in net cash flow from operating activities, resulting in a negative cash flow of ¥598,622.65 for the year-to-date period[9] - Cash inflow from operating activities was CNY 642,729,723.94, an increase from CNY 507,761,446.92 in the previous year[27] - Cash flow from investing activities resulted in a net outflow of CNY 59,583,541.99, compared to a net outflow of CNY 39,001,358.06 in the previous year[28] - Cash flow from financing activities generated a net inflow of CNY 207,913,854.07, recovering from a net outflow of CNY -7,966,789.63 in the same period last year[28] - The ending cash and cash equivalents balance was CNY 352,866,514.95, up from CNY 312,683,285.79 at the end of the previous year[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,674[11] - The largest shareholder, Changjiang Industrial Investment Group Co., Ltd., holds 24.84% of the shares, totaling 87,592,065 shares[11] - The top ten shareholders hold a total of 50,052,962 unrestricted shares, representing a significant portion of the company's equity[11] - The company has not identified any related party relationships among its top ten shareholders, except for Changjiang Industrial Investment Group Co., Ltd.[12] Strategic Initiatives - The company plans to implement a "mixed reform" strategy to enhance its R&D capabilities by establishing a subsidiary with Wuhan Tongtai Qixin Enterprise Management Consulting Partnership[15] - A capital increase of RMB 45 million was approved for its wholly-owned subsidiary, Hubei Guangji Pharmaceutical Jikang Pharmaceutical Co., Ltd., to support its diversification strategy[18] - The company has completed the registration of its subsidiary, Hubei Guangji Pharmaceutical Technology Co., Ltd., to strengthen its product development platform[15] - The company has signed an agreement to acquire state-owned land use rights totaling 154.63 acres for RMB 56,473,404.54[18] - The company provided a guarantee for its subsidiary's transaction with a maximum amount of RMB 120 million for equipment leasing[17]